Clinical trial
A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
NCT01749956 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
- Lead sponsor
- SCRI Development Innovations, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- September 30, 2015
- Enrollment
- 39 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
rectal cancer